563 related articles for article (PubMed ID: 34712202)
1. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
2. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
3. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
4. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
[No Abstract] [Full Text] [Related]
5. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy.
Narahira A; Yanagi T; Cho KY; Nakamura A; Miyoshi H; Hata H; Imafuku K; Kitamura S; Shimizu H
J Dermatol; 2017 Apr; 44(4):e70. PubMed ID: 27608187
[No Abstract] [Full Text] [Related]
6. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.
Iglesias P; Sánchez JC; Díez JJ
Pituitary; 2021 Aug; 24(4):630-643. PubMed ID: 33761049
[TBL] [Abstract][Full Text] [Related]
7. Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab.
Pierrard J; Petit B; Lejeune S; Seront E
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31439558
[TBL] [Abstract][Full Text] [Related]
8. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
[TBL] [Abstract][Full Text] [Related]
10. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.
Zeng MF; Chen LL; Ye HY; Gong W; Zhou LN; Li YM; Zhao XL
Medicine (Baltimore); 2017 Nov; 96(44):e8426. PubMed ID: 29095280
[TBL] [Abstract][Full Text] [Related]
11. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
12. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
13. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab.
Kitajima K; Ashida K; Wada N; Suetsugu R; Takeichi Y; Sakamoto S; Uchi H; Matsushima T; Shiratsuchi M; Ohnaka K; Furue M; Nomura M
Jpn J Clin Oncol; 2017 May; 47(5):463-466. PubMed ID: 28334791
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
Martins Machado C; Almeida Santos L; Barroso A; Oliveira MJ
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466960
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.
Suzuki Y; Ishiguro S; Shimada H; Ohgami M; Suzuki M
Cancer Chemother Pharmacol; 2024 Jun; 93(6):633-638. PubMed ID: 38148336
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
18. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor].
Cho KY; Miyoshi H; Nakamura A; Kurita T; Atsumi T
Endocr J; 2017 Feb; 64(2):235-236. PubMed ID: 28070057
[No Abstract] [Full Text] [Related]
19. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
[No Abstract] [Full Text] [Related]
20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
